Is Moderna Stock a Buy Now After the U.K.'s Omicron Vaccine Approval?

Shares of COVID-19 vaccine pioneer Moderna (NASDAQ: MRNA) moved higher on Monday morning, rising more than 3% as the company announced more good news with its virus-fighting efforts. Specifically, Moderna said that it has received approval for use in the U.K. for what the company is calling its "next-generation COVID-19 vaccine." The body oversees immunization approvals in the U.K., and this is the first time that it or any other regulatory agency has approved a bivalent vaccine designed to address the omicron variant.